Modulation of the Epithelial-Immune Cell Crosstalk and Related Galectin Secretion by DP3-5 Galacto-Oligosaccharides and β-3'Galactosyllactose

Biomolecules. 2022 Feb 28;12(3):384. doi: 10.3390/biom12030384.

Abstract

Prebiotic galacto-oligosaccharides (GOS) were shown to support mucosal immune development by enhancing regulatory-type Th1 immune polarization induced by synthetic CpG oligodeoxynucleotides (TLR9 agonist mimicking a bacterial DNA trigger). Epithelial-derived galectin-9 was associated with these immunomodulatory effects. We aimed to identify the most active fractions within GOS based on the degree of polymerization (DP), and to study the immunomodulatory capacities of DP3-sized β-3'galactosyllactose (β-3'GL) using a transwell co-culture model of human intestinal epithelial cells (IEC) and activated peripheral blood mononuclear cells (PBMC). IEC were apically exposed to different DP fractions of GOS or β-3'GL in the presence of CpG, and basolaterally co-cultured with αCD3/CD28-activated PBMC, washed, and incubated in fresh medium for IEC-derived galectin analysis. Only DP3-5 in the presence of CpG enhanced galectin-9 secretion. DP3-sized β-3'GL promoted a regulatory-type Th1 response by increasing IFNγ and IL-10 or galectin-9 concentrations as compared to CpG alone. In addition, IEC-derived galectin-3, -4, and -9 secretion was increased by β-3'GL when combined with CpG. Therefore, the GOS DP3-5 and most effectively DP3-sized β-3'GL supported the immunomodulatory properties induced by CpG by enhancing epithelial-derived galectin secretion, which, in turn, could support mucosal immunity.

Keywords: galacto-oligosaccharides; galectins; immunomodulation; intestinal epithelial cells; mucosal immunity; β-3′galactosyllactose.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Epithelial Cells*
  • Galectins / pharmacology
  • HT29 Cells
  • Humans
  • Leukocytes, Mononuclear*
  • Oligosaccharides / pharmacology

Substances

  • Galectins
  • Oligosaccharides